Classification and related instructions of Lemborexant as a Class II drug

Lemborexant is pharmacologically classified as a "dual orexin receptor antagonist" and belongs to the category of "Class II sedative-hypnotic drugs" among new central nervous system drugs. The "Class II drugs" mentioned here do not refer to the traditional regulatory classification (such as the classification of prescription drugs and over-the-counter drugs into Class I and Class II), but refer to the second-generation sleep aid types whose mechanism of action is different from traditional hypnotics. Unlike previous benzodiazepines that rely on GABA-A receptor-enhancing effects, leborexine blocks orexin-1 and orexin-2 receptor signals in the brain's arousal system, thereby inhibiting the activity of the awake neural network and restoring sleep to a physiological state.

In the pharmacological classification system, leborexan is classified into the non-GABA receptor drug category of "Psycho-Nervous Drugs-Hypnosedatives". Due to its innovative mechanism and low risk of dependence, the U.S. FDA classifies it as a prescription drug but not a highly controlled psychotropic drug. It is only classified as a lightly controlled drug in some countries (such as the Schedule IV classification in the United States), mainly due to preventive considerations of abuse potential.

In the Chinese Pharmacopoeia and drug management system, leborexan has not been officially included in the local classification catalog, so its international pharmacological classification definition is usually referred to. According to the classification of Chinese clinical pharmacy, leborexan can be regarded as a "second type centrally acting hypnotic drug" and is used to treat chronic insomnia, sleep disorder, sleep maintenance disorder and other neurological sleep disorders. The main advantage of this drug is that it does not cause significant cognitive impairment or residual daytime sleepiness, and it is not likely to cause rebound or drug resistance after discontinuation.

From the perspective of drug supervision, the prescription management of Lebraxen is relatively strict. Doctors need to evaluate the patient's sleep disorder type, mental status and drug interaction risk when prescribing. Long-term use requires regular follow-up visits and monitoring of changes in sleep quality and daytime alertness. Compared with traditional sedatives, it is less dependent and suitable for long-term or intermittent use, but it still needs to be taken according to the doctor's instructions.

Reference materials:https://medlineplus.gov/druginfo/meds/a620039.html